Presentation
7 March 2022 The use of bioconjugates of porphyrin to overcome ABC drug transporter-mediated drug resistance
Author Affiliations +
Abstract
Rationally designed bioconjugates of photosensitizers have been shown to enhance the photochemical effect of photodynamic therapy (PDT) via altering the sub-cellular localization of the photosensitizers or modulating the function of ATP-binding cassette (ABC) transporters. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are the two key members that contribute to chemoresistance and PDT resistance in cancer. Here, we introduce a porphyrin-based phospholipid conjugation strategy to circumvent and inhibit the efflux function of ABC drug transporters. Our results show the porphyrin-phospholipid conjugate enhances the photosensitizer accumulation and modulates the enzymatic activity and protein integrity of ABCB1 and ABCG2.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Barry J. Liang, Suresh V. Ambudkar, and Huang-Chiao Huang "The use of bioconjugates of porphyrin to overcome ABC drug transporter-mediated drug resistance", Proc. SPIE PC11940, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic and Photobiomodulation Therapy XXX, (7 March 2022); https://doi.org/10.1117/12.2609732
Advertisement
Advertisement
KEYWORDS
Resistance

Cancer

Photodynamic therapy

Proteins

Breast cancer

Modulation

Molecules

RELATED CONTENT

Recent research progress on the role of BCL2 in cancer...
Proceedings of SPIE (March 24 2023)
Protease-mediated drug delivery
Proceedings of SPIE (December 15 2003)
Role of multidrug resistance in photodynamic therapy
Proceedings of SPIE (June 01 1992)
Carrier systems in PDT on the way to novel...
Proceedings of SPIE (January 12 1995)
Immunologic Targeting Of Cancer Cells
Proceedings of SPIE (June 13 1989)

Back to Top